Similar articles

• CCK receptor antagonists.

  Dunlop J. Dunlop J. Gen Pharmacol. 1998 Oct;31(4):519-24. doi: 10.1016/s0306-3623(98)00078-0. Gen Pharmacol. 1998. PMID: 9792209 Review.
• Selectivity of cholecystokinin (CCK) receptor antagonists, MK-329 and L-365,260, for axonally-transported CCK binding sites on the rat vagus nerve.

  Mercer JG, Lawrence CB. Mercer JG, et al. Neurosci Lett. 1992 Mar 30;137(2):229-31. doi: 10.1016/0304-3940(92)90410-9. Neurosci Lett. 1992. PMID: 1374868
• Molecular design of potent specific antagonists for the gastrin and cholecystokinin receptors.

  Evans BE. Evans BE. Z Gastroenterol Verh. 1991 Mar;26:269-71. Z Gastroenterol Verh. 1991. PMID: 1714170
• Blockade of morphine place conditioning by the CCKA receptor antagonist devazepide.

  Higgins GA, Nguyen P, Sellers EM. Higgins GA, et al. Eur J Pharmacol. 1991 May 17;197(2-3):229-30. doi: 10.1016/0014-2999(91)90528-x. Eur J Pharmacol. 1991. PMID: 1915570 No abstract available.
• CCK antagonists and CCK-monoamine interactions in the control of satiety.

  Cooper SJ, Dourish CT, Clifton PG. Cooper SJ, et al. Am J Clin Nutr. 1992 Jan;55(1 Suppl):291S-295S. doi: 10.1093/ajcn/55.1.291s. Am J Clin Nutr. 1992. PMID: 1728842 Review.